Tampa, FL Clinical Trials Report — April 2026

For Tampa residents exploring clinical trial opportunities, April 2026 presents a critical window to participate in studies nearing their enrollment deadlines. Across the city, 74 clinical trials are scheduled to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 5 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

New Opportunities for Healthy Volunteers and Specific Conditions

This month, Tampa welcomed 10 new clinical trials, a slight decrease from the 11 trials that launched in March 2026. Despite this small dip, the city continues to offer diverse research opportunities. Notably, 5 of these new trials are actively seeking healthy volunteers, adding to the total of 58 trials currently recruiting healthy participants in Tampa.

New trials are addressing a range of conditions, including adult obesity, anxiety, depression, HIV, and HIV prevention. For those without specific conditions, the opportunity to contribute to general health research is significant.

Spotlight on Notable New Research

April brings several high-profile new trials to Tampa, including important Phase 2 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• The University of South Florida is sponsoring NCT07505381, "Behavioral Parent Training to Address Early Childhood Disruptive Behavior Using the Helping Our Toddlers, Developing Our Children's Skills (HOT DOCS) Program and the Developing Our Children's Skills Kindergarten-5th Grade (DOCS K-5) Program." This study, aiming for 800 participants, investigates group-delivered behavioral parent training interventions for caregivers of children ages 0-12 years.
• Kinaset Therapeutics Inc is launching NCT07532265, "A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma." This Phase 2 dose-ranging study seeks 512 participants to evaluate Frevecitinib over a 12-week treatment period in patients with severe asthma not controlled with standard ICS/LABA therapy.
• Virogen Biotechnology Inc. is initiating NCT07529405, "A Study of VG712 in Patients With Mycosis Fungoides." This Phase 2 study (CurbMF-001) will evaluate the safety and efficacy of VG712, a recombinant anti-CD3 immunotoxin, compared with mogamulizumab in 386 participants.
• Westat is leading NCT07510048, "Combatting HIV Or Other STIs Early (CHOOSE) in an RCT of mHealth Tool Support." This Phase 2 project, involving 200 participants, aims to optimize and assess the efficacy and cost of the PrEP Choice integrated mHealth package on PrEP initiation and adherence among young people.
• Eccogene is sponsoring NCT07505303, "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial." This Phase 2 trial, designed for 160 participants, will evaluate the effect of oral ECC4703 on body weight reduction and liver fat content.
• Eli Lilly and Company is conducting NCT07533019, "A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo." This Phase 2 study, seeking 60 participants, will evaluate the tolerability and side effects of LY4005130 administered intravenously.

Conditions with Impending Deadlines

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on neurological conditions, various cancers, and renal health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Myasthenia gravis (3 trials)
• Cholangiocarcinoma (2 trials)
• Myelodysplastic syndromes (2 trials)
• Stage IV lung cancer AJCC V8 (2 trials)
• Pancreatic cancer (2 trials)
• Renal impairment (2 trials)
• Advanced breast cancer (1 trial)
• Acute undifferentiated leukemia (1 trial)
• Acute leukemia (1 trial)
• Aged (1 trial)

Tampa's Leading Research Facilities

Tampa is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Moffitt Cancer Center (284 trials)
• University of South Florida (108 trials)
• Tampa General Hospital (59 trials)
• Saint Joseph's Hospital/Children's Hospital-Tampa (40 trials)
• Research Site (33 trials)
• Moffitt Cancer Center - McKinley Campus (27 trials)
• Moffitt Cancer Center-International Plaza (24 trials)
• St. Joseph's Children's Hospital (9 trials)
• Neurocrine Clinical Site (8 trials)
• Clinical Site (8 trials)

These institutions offer a broad spectrum of research, with Moffitt Cancer Center specializing in oncology, and the University of South Florida and Tampa General Hospital contributing to diverse medical fields.

Overall Research Landscape in Tampa

Currently, Tampa, FL, hosts a robust research environment with 1,029 clinical trials actively recruiting across 438 research facilities. The trend for new trial openings in Tampa has seen some fluctuation over the past six months, with 10 new trials this April following 14 in March, 13 in February, 20 in January, 25 in December, and 22 in November. This month's new trials are predominantly drug trials (5), followed by behavioral (2) and device (2) trials.

Broadening Your Search: Nearby Florida Options

While Tampa offers a vast array of clinical trial opportunities, individuals may also find options in other communities within Florida. Cities with active trials include Miami (16 trials), Jacksonville (7 trials), Orlando (6 trials), Gainesville (3 trials), Miami Lakes (3 trials), Sarasota (2 trials), Fort Myers (2 trials), and Boca Raton (2 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 10 new trials launched this month, 9 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children, and 1 is specifically for male participants. Academic institutions, particularly the University of South Florida, continue to play a vital role in Tampa's research ecosystem, sponsoring 3 of the new trials this month. Industry sponsors like Eli Lilly and Company, Kinaset Therapeutics Inc, and Eccogene are also driving significant research efforts.

As spring progresses, Tampa's research community will continue to advance medical innovation, offering diverse opportunities for those looking to contribute to future health treatments.